OV101

Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study

Authors: Dejan B Budimirovic, Kelli C Dominick, Lidia V Gabis, Maxwell Adams, Mathews Adera, Linda Huang, Pamela Ventola, Nicole R Tartaglia, Elizabeth Berry-Kravis

Journal: Frontiers in Pharmacology

Year Published: 2021

Background: Fragile X syndrome (FXS), the most common single-gene cause of intellectual disability and autism spectrum disorder (ASD), is caused by a >200-trinucleotide repeat expansion in the 5′ untranslated region of the fragile X mental retardation […]

Back to Publications